ClinicalTrials.Veeva

Menu
R

Royalderm | Warsaw, Poland

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

ESK-001
BIIB059
TAK-279
Spesolimab
Litifilimab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 5 total trials

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: Litifilimab
Drug: Placebo

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting
Plaque Psoriasis
Drug: TAK-279
Drug: Placebo

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: Apremilast

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001

Trial sponsors

A
Biogen logo
Boehringer Ingelheim logo
Takeda logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems